The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
Cariad Chester
No relevant relationships to disclose
Serena Chang
No relevant relationships to disclose
John F. Kurland
Employment or Leadership Position - Bristol-Myers Squibb
Idit Sagiv-Barfi
No relevant relationships to disclose
Debra Czerwinski
No relevant relationships to disclose
Amanda Rajapaksa
No relevant relationships to disclose
Erin Waller
No relevant relationships to disclose
Mohith Sadaram
No relevant relationships to disclose
Lori Richards
No relevant relationships to disclose
Lewis J. Cohen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christoph Matthias Ahlers
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Maria Jure-Kunkel
Employment or Leadership Position - Bristol-Myers Squibb
Holden Maecker
No relevant relationships to disclose
Ronald Levy
No relevant relationships to disclose
Holbrook Edwin Kohrt
No relevant relationships to disclose